Welcome to ETFdb.com. Please help us personalize your experience.
Thank you for your submission, we hope you enjoy your experience

Select the one that best describes you
ALERT

September 2016 ETF Edge Just Released - Download Now

Etfdb logo
  • ETF
  • IRY
    Pricing Data
    $47.68
    Change: $0.95 (-0.02%)
    Time: 09/29/16
    Previous Close: $48.63
  • Category
  • Health & Biotech Equities
Last Updated:

Profile

Vitals

Trading Data

Open: - Volume -
Day Lo - Day Hi -
  • 52 Week Lo: $43.21
  • 52 Week Hi: $50.27
  • AUM: $50.8 M
  • Shares: 1.1 M

Investment Themes

Historical Trading Data

  • 1 Month Avg. Volume: 5,330
  • 3 Month Avg. Volume: 12,671

Alternative ETFs in the Health & Biotech Equities Category

Sign Up for Pro to Unlock Data Sign Up
Type Ticker Expense Ratio Assets Avg. Daily Vol YTD Return
Cheapest
Largest (AUM)
Most Liquid (Volume)
Top YTD Performer

Analyst Report

This ETF offers exposure to the health care sector internationally, focusing on companies in developed and emerging markets outside of the U.S. Given the international and sector-specific nature of this fund, IRY probably doesn't belong in a long-term, buy-and-hold portfolio; it will be more useful for investors looking to implement a tilt towards the generally stable health care sector without including U.S. stocks. IRY can also be useful as part of a pairs trade, such as long IRY / short XLV. Perhaps not surprisingly, IRY is somewhat concentrated; the basket of securities is relatively shallow, and a few big names account for a significant portion of total assets. And while the underlying index theoretically includes emerging market exposure, in practice IRY is exclusively a developed market fund. For a limited segment of investors, this fund may be a useful tool; those looking for U.S. exposure may prefer XLV or RYH, while those seeking more global representation may prefer IXJ.

Realtime Rating

Sign Up for Pro to Unlock Data Sign Up

Realtime Rating Summary

The adjacent table gives investors an individual Realtime Rating for IRY on several different metrics, including liquidity, expenses, performance, volatility, dividend, concentration of holdings in addition to an overall rating. The "A+ Metric Rated ETF" field, available to ETFdb Pro members, shows the ETF in the Health & Biotech Equities with the highest Metric Realtime Rating for each individual field. To view all of this data, sign up for a free 14-day trial for ETFdb Pro. To view information on how the ETFdb Realtime Ratings work, click here.

Compare to another ETF

View the Category Report

IRY Overall Realtime Rating:

A+ Overall Rated ETF:

Metric Metric Realtime Rating A+ Metric Rated ETF
Liquidity B- n/a
Expenses B+ n/a
Performance
Volatility
Dividend
Concentration

Knowledge Centers

IRY In-Depth Analysis

The following tables and charts contain in-depth metrics for this ETF and compare it to similar peer ETFs within its ETFdb Category.

IRY Holdings

Filings Data as of: Sep 05, 2016
Sign Up for Pro to Unlock Data Sign Up

Concentration Analysis

This section compares how balanced and deep this ETF is relative to the peer group ETFdb Category.

Number of Holdings
Rank:
149
Category Low
Category High
% Assets in Top 10
Rank:
55.89%
Category Low
Category High

Asset Allocation

Asset Percentage
U.S. Stocks 3.99%
International Stocks 95.51%
U.S. Bonds 0.0%
International Bonds 0.0%
Preferred Stock 0.1%
Convertibles 0.0%
Cash 0.32%
Other 0.1%

Sector Breakdown

Sector Percentage
Health Care 97.23%
Technology 1.42%
Basic Materials 0.68%
Consumer Cyclical 0.12%
Financial Services 0.0%
Real Estate 0.0%
Consumer Defensive 0.0%
Communication Services 0.0%
Energy 0.0%
Industrials 0.0%
Utilities 0.0%

Market Cap Breakdown

Market Cap Percentage
Giant 61.33%
Large 23.92%
Medium 12.84%
Small 1.1%
Micro 0.0%

Region Breakdown

Region Percentage
Europe 36.42%
Japan 17.41%
Australia 5.06%
U.S. 3.99%
Asia (Developed) 3.2%
Canada 0.74%
Asia (Emerging) 0.06%
Latin America 0.0%
Africa 0.0%
Middle East 0.0%

Market Tier Breakdown

Region Percentage
Developed 99.43%
Emerging 0.06%

Country Breakdown

Country Percentage
Switzerland 25.05%
Belgium 0.84%
Japan 17.41%
United Kingdom 16.15%
Germany 9.74%
France 8.38%
Denmark 6.93%
Australia 4.43%
United States 3.99%
South Korea 2.73%
Other 4.35%

IRY Expenses & Fees

This section compares the cost efficiency of this ETF to peers in the same ETFdb Category.

Sign Up for Pro to Unlock Data Sign Up

Expenses Ratio Analysis

ETF Average
0.576%
ETF Wtd. Average
0.26%
Category Average
0.48%
Expense Ratio
Rank:
0.40%
Category Low
Category High

Commission Free Trading

This ETF is not currently available for commission free trading on any platforms.

Category Commission Free Trading

There are 3 other ETFs in the Health & Biotech Equities ETFdb Category that are also eligible for commission free trading:

IRY Performance

This section shows how this ETF has performed relative to its peer group ETFdb Category.

1 Week Return
Rank:
-2.36%
Category Low
Category High
4 Week Return
Rank:
1.22%
Category Low
Category High
13 Week Return
Rank:
-1.57%
Category Low
Category High
26 Week Return
Rank:
3.38%
Category Low
Category High
Year to Date Return
Rank:
-3.55%
Category Low
Category High
1 Year Return
Rank:
0.81%
Category Low
Category High
3 Year Return
Rank:
20.40%
Category Low
Category High
5 Year Return
Rank:
75.01%
Category Low
Category High

Charts

The following charts can be customized to display historical performance in a number of different formats, including line charts, bar charts, and candlesticks. Time periods can be adjusted to increase or decrease the period shown, ranging from five minutes to several months.

The following chart also includes the option to compare the performance of IRY relative to other ETFs and benchmarks or to include indicators such as Bollinger Bands, relative strength, and moving averages.

IRY Valuation

This section shows how the P/E multiple of this ETF compares to the peer group ETFdb Category.

Sign Up for Pro to Unlock Data Sign Up
P/E Ratio
Rank:
18.49
Category Low
Category High

As of Aug 25 2016

IRY Dividend

This section shows how the dividend yield of this ETF compares to the peer group ETFdb Category.

Sign Up for Pro to Unlock Data Sign Up
Dividend
$0.10
Dividend Date
2016-09-16
Annual Dividend Rate
$1.04
Annual Dividend Yield
Rank:
2.14%
Category Low
Category High

As of Aug 25, 2016

IRY Technicals

Sign Up for Pro to Unlock Data Sign Up

Volatility Analysis

This section shows how the volatility of this ETF compares to the peer group ETFdb Category.

5 Day Volatility
Rank:
69.19%
Category Low
Category High
20 Day Volatility
Rank:
15.17%
Category Low
Category High
50 Day Volatility
Rank:
12.22%
Category Low
Category High
200 Day Volatility
Rank:
16.02%
Category Low
Category High
Beta
Rank:
1.15
Category Low
Category High
Standard Deviation
Rank:
1.38%
Category Low
Category High

Technicals

  • 20 Day MA: $47.93
  • 60 Day MA: $48.51
  • MACD 15 Period: -0.27
  • MACD 100 Period: -0.45
  • Williams % Range 10 Day: 82.93
  • Williams % Range 20 Day: 64.94
  • RSI 10 Day: 44
  • RSI 20 Day: 46
  • RSI 30 Day: 48
  • Ultimate Oscillator: 47

Bollinger Brands

  • Lower Bollinger (10 Day): $47.36
  • Upper Bollinger (10 Day): $49.02
  • Lower Bollinger (20 Day): $46.94
  • Upper Bollinger (20 Day): $48.88
  • Lower Bollinger (30 Day): $46.95
  • Upper Bollinger (30 Day): $48.97

Support & Resistance

  • Support Level 1: $47.50
  • Support Level 2: $47.31
  • Resistance Level 1: $47.94
  • Resistance Level 2: $48.19

Stochastic

  • Stochastic Oscillator %D (1 Day): 50.99
  • Stochastic Oscillator %D (5 Day): 38.03
  • Stochastic Oscillator %K (1 Day): 50.75
  • Stochastic Oscillator %K (5 Day): 49.91

Fact Sheet

Fact sheets are issued by the ETF provider and framed by ETFdb.com. Information contained within the fact sheet is not guaranteed to be timely or accurate.

2014 Morningstar, Inc. All Rights Reserved. The information contained herein: ( 1 ) is proprietary to Morningstar and/or its content providers; ( 2 ) may not be copied or distributed; and ( 3 ) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.